- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.05. | Bristol Myers deepens AI investment with Anthropic deal | ||
| 20.05. | Oorja, run by Acceleron veterans, launches to make new fibrosis drugs | ||
| 20.05. | Immunovant's potential autoimmune 'blockbuster'; Wave's RNA editing update | ||
| 19.05. | BioMarin drug acquired in buyout misses goal in rare disease study | ||
| 19.05. | A migraine drugmaker heads to the public markets through reverse merger | ||
| 19.05. | Relay drug shows early promise against rare blood vessel diseases | ||
| 18.05. | FDA approves AstraZeneca's new kind of hypertension drug | ||
| 18.05. | Merck ADC, licensed from China, hits mark in first big global trial | ||
| 18.05. | Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug | ||
| 18.05. | Regeneron immunotherapy combo comes up short in melanoma trial | ||
| 18.05. | Unlocking more value from mature drug products through strategic outsourcing | ||
| 15.05. | FDA hold puts Aardvark Prader-Willi drug in limbo | ||
| 15.05. | Supreme Court preserves access to abortion pill by mail | ||
| 15.05. | Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers | ||
| 15.05. | India's pharma industry is going global. But can it catch up to China? | ||
| 14.05. | Create Medicines raises $122M to bolster in vivo CAR-T therapies | ||
| 14.05. | Biogen pushing tau drug forward despite Alzheimer's study failure | ||
| 14.05. | With new data, Regenxbio to seek FDA approval of Duchenne gene therapy | ||
| 13.05. | FDA's leadership void leaves biotech with renewed 'uncertainty' | ||
| 13.05. | Lilly data point to 'maintenance' strategies for GLP-1 weight loss | ||
| 13.05. | Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B | ||
| 13.05. | [Podcast] Closing the Distance in Cancer Care | ||
| 12.05. | FDA chief Marty Makary resigns from agency, ending tumultuous tenure | ||
| 12.05. | Arvinas, Pfizer find new partner for 'Protac' breast cancer drug | ||
| 12.05. | Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.